Savara shares surge 17.35% intraday after FDA designates lung disease drug as promising.

Savara Inc. surged 17.35% intraday after securing a $149.5M public offering and receiving positive FDA designation for its lung disease drug, MOLBREEVI. The funding boost enhanced liquidity for clinical trials and commercialization efforts, while recent efficacy data from the IMPALA-2 trial reinforced confidence in the therapy’s potential for autoimmune PAP. Analysts highlighted the improved balance sheet and strategic focus on high-impact projects, aligning with the stock’s sharp rally as traders reacted to regulatory progress and capital-raising success.